TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06225804
Drug: ABSK112
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the escalation part, patients will receive a single dose of oral ABSK112 on Cycle1 Day1 only, and then patients will continuously receive ABSK112 once daily (QD) or twice daily (BID) in subsequent cycles. In the expansion part, patients will each be treated at the selected RDE dose level.
Study: NCT05975554
Drug: Interleukin-2 [IL-2]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 sequential days of treatment (1.5MIU/day subcutaneously)
Study: NCT05406440
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8189 dose-matching placebo tablets will be administered orally QD.
Study: NCT06117904
Drug: Symptomatic treatment only
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group included twenty-five patients given symptomatic therapy 3 times daily for 7 weeks.~These therapies included anti-fungal agents (Miconaz oral gel), topical anesthetics and anti-inflammatory drugs (BBC oral spray), topical analgesic gel (Oracure gel), sodium bicarbonate mouthwash (Alkamisr sachets).
Study: NCT05481333
Drug: REGN7999
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending IV or SC dose administered per protocol
Study: NCT05975788
Drug: Staphylococcus and Neisseria Tablets
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staphylococcus and Neisseria tablets is used as an adjuvant treatment drug for respiratory disease in acute attack period, such as chronic tracheitis, bronchitis and various types of colds. It has been proved to effectively shorten the course of disease. In this study, Staphylococcus and Neisseria tablets will be administered with 4 tablets each time and 3 times a day, and treatment period ranges from 3 to 6 months according to clinicians.
Study: NCT04858425
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo tablets 400 mg 3 times daily for 14 days
Study: NCT05907850
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule compounded to be similar in appearance to the active intervention
Study: NCT05031806
Drug: iNexin™ (0.08% aCT1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.randomized 7:3 for each active concentration to Vehicle.
Study: NCT05031806
Drug: iNexin™ (0.4% aCT1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.
Study: NCT04926246
Drug: R1: Reference Product X
Approvals — FDA: no, EMA: no, PMDA: no
Description: under fasted conditions
Study: NCT04926246
Drug: T1: Test Product M
Approvals — FDA: no, EMA: no, PMDA: no
Description: under fasted conditions
Study: NCT04926246
Drug: T2: Test Product N
Approvals — FDA: no, EMA: no, PMDA: no
Description: under fasted conditions
Study: NCT04926246
Drug: T3: Test Product O
Approvals — FDA: no, EMA: no, PMDA: no
Description: under fasted conditions
Study: NCT04926246
Drug: T4: Test Product O
Approvals — FDA: no, EMA: no, PMDA: no
Description: under fed conditions
Study: NCT04926246
Drug: R2: Reference Product Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: under fasted conditions
Study: NCT04926246
Drug: T5: Test Product P
Approvals — FDA: no, EMA: no, PMDA: no
Description: under fasted conditions
Study: NCT04926246
Drug: T6: Test Product P
Approvals — FDA: no, EMA: no, PMDA: no
Description: under fed conditions
Study: NCT04926246
Drug: T7: Test Product Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: under fasted conditions
Study: NCT04926246
Drug: R3: Reference Product Z
Approvals — FDA: no, EMA: no, PMDA: no
Description: under fasted conditions
Study: NCT04926246
Drug: T8: Test Product S
Approvals — FDA: no, EMA: no, PMDA: no
Description: under fasted conditions
Study: NCT04926246
Drug: T9: Test Product S
Approvals — FDA: no, EMA: no, PMDA: no
Description: under fed conditions
Study: NCT04926246
Drug: T10: Test Product U
Approvals — FDA: no, EMA: no, PMDA: no
Description: under fasted conditions
Study: NCT05235542
Drug: Capecitabine tablets
Normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral,Specified dose on specified days
Study: NCT04888585
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Injection
Study: NCT04927975
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT04700007
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: injections of isotonic saline (0.05 ml, 0.9%) as vehicle will be performed.
Study: NCT05759897
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05479240
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive Capecitabine, 1000mg/m2, day 1-14 of every 3 weeks for 6 cycles
Study: NCT05528328
Drug: Placebo (saline solution)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline solution) administered in identic al vials
Study: NCT06141980
Drug: DWP16001 0.3 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP16001 0.3mg, Tablets, Orally, Once daily
Study: NCT05969236
Drug: MDI-1228_mesylate Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI-1228_mesylate Ophthalmic Solution includes 2 strengths:~* 0.1% (0.4 mL \[0.4 mg\] free base)~* 0.3% (0.4 mL \[1.2 mg\] free base)
Study: NCT05969236
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The components employed in the placebo formulation are the same as those used for the active formulation except MDI-1228_mesylate is absent.
Study: NCT05054426
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous versus intrathecal methotrexate
Study: NCT04756804
Drug: 70% v/v Isopropyl Alcohol Surgical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient preoperative skin preparation
Study: NCT04756804
Drug: 2%w/v Chlorhexidine Gluconate / 70% v/v Isopropyl Alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient preoperative skin preparation
Study: NCT00002357
Drug: HBY 097
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05935332
Drug: RPT193
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPT193 is an antagonist of the C-C motif chemokine receptor 4 (CCR4) that inhibits CCR4-mediated chemotaxis toward both CCL22 and CCL17
Study: NCT05007262
Drug: Calcium dobesilate capsules
Normalized name: calcium dobesilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule at a time, tid,po.(morning, midday, and evening), used on an empty stomach.
Study: NCT06141447
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mL bag of normal saline alone
Study: NCT05729932
Drug: Intransal opioid
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind opioid and placebo doses, administered intranasal route
Study: NCT05923008
Drug: IBI130
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive IBI130 until unacceptable toxicity, disease progression, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or for a maximum of 24 months of treatment, whichever occurs first.
Study: NCT05195541
Drug: CU-20401
Normalized name: Cu 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection in the subcutaneous fat area，0.2ml
Study: NCT05012644
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor
Study: NCT05159518
Drug: PRT2527
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRT2527 will be administered by intravenous infusion
Study: NCT02245945
Drug: TFV 1% vaginal gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5.
Study: NCT02245945
Drug: HEC Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel contains hydroxyethylcellulose (HEC) as the gel thickener, purified water, sodium chloride, sorbic acid and sodium hydroxide. The gel is isotonic and formulated at a pH of 4.4. Each pre-filled applicator will contain approximately 4 mL of placebo gel for delivery.
Study: NCT05702970
Drug: Ferric Carboxymaltose 50 MG/ML
Normalized name: ferric carboxymaltose 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group \[standard of care\]: administration of FCM (Ferinject®) with a dose between 500 and 2000 mg (depending on body weight and Hb values), to be administered in 1 or 2 doses (time 0 ± 6 weeks) with possible additional administration of 500 mg at week 12 in case of persistent ID.
Study: NCT04725201
Drug: Sham
Normalized name: SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: See sham comparator arm description for intervention description.
Study: NCT01353482
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomised into the placebo arm of the trial will receive Cisplatin and Pemetrexed as standard as well as placebo.
Study: NCT05039723
Drug: Radiesse, Xeomin, Belotero
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rejuvenation with Radiesse, Xeomin, Belotero
Study: NCT06445374
Drug: Inhaled Epinephrine
Normalized name: epinephrine Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg per inhalation.~The maximum proposed dose to be administered is 1.0 mg (consisting of 8 inhalations of 0.125 mg over 6 minutes).
Study: NCT06101316
Drug: CB06-036
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB06-036 Capsule
Study: NCT04881799
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily injection
Study: NCT06421948
Drug: cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: A combination of cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone (CHOP) will be administered for 6 cycles in patients responded to treatment.
Study: NCT04588285
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo medication (60 mg) from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)
Study: NCT06471218
Drug: SHR-1918; SHR-1918 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1918/SHR-1918 Placebo,two administration
Study: NCT05083949
Drug: Glifage®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glifage® 850mg (R2)
Study: NCT05391048
Drug: IMP4297(20mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of IMP4297 administered under fasting conditions 5\*20 mg capsules in first intervention period and 10\*10 mg capsules in second intervention period (after washout period: at least 7 days)
Study: NCT05391048
Drug: IMP4297(10mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of IMP4297 administered under fasting conditions 10\*10 mg capsules in first intervention period and 5\*20 mg capsules in second intervention period (after washout period: at least 7 days)
Study: NCT05481970
Drug: fentanyl,propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: In group (B) for induction of anesthesia, patients will receive propofol 2-3mg/kg, fentanyl 1-2mcg/kg and atracurium 0.5 mg/kg as a muscle relaxant to facilitate intubation. Fentanyl bolus doses of 0.5-1 mcg/kg will be given to keep BIS score 40-60 during surgery.
Study: NCT04890470
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intranasal administration of placebo
Study: NCT05599971
Drug: intralesional injection of 5- Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 patients will receive intralesional injection of 5- Fluorouracil (50mg/ml) in full concentration into the wart using a 27- gauge insulin syringe till the entire lesion begins to puff up. The maximum dose injected per session will be 2ml of 5-FU. Selected patients will receive one session every 2 weeks till complete clearance or up to 5 sessions.
Study: NCT06228443
Drug: ARAVA® 20 mg Film-coated Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARAVA® 20 mg Tablets (Reference Drug)
Study: NCT06630208
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take pharmacological treatment prescribed by the cardiologist.
Study: NCT05605704
Drug: atherolive
Approvals — FDA: no, EMA: no, PMDA: no
Description: In each study population(Diabetic), the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
Study: NCT04859426
Drug: DBPR108 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: DBPR108, tablet, oral
Study: NCT05878535
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablets. Prescribed: Once daily PO with meals and 200 mL of water.
Study: NCT04753749
Drug: Shortened DAPT followed by P2Y12 inhibitor monotherapy (cessation of aspirin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive DAPT during 1 month post procedure, followed by P2Y12 inhibitor monotherapy (cessation of aspirin) for the next 11 months
Study: NCT04753749
Drug: Standard DAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive standard treatment: P2Y12 inhibitor and aspirin (DAPT) during 12 months after procedure
Study: NCT05225857
Drug: AGA2118
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1 - SAD study: SAD participants in various cohorts will receive various single dose of AGA2118 via either SC or IV.~Part 2 - MAD study: MAD participants in various cohorts will receive various multiple doses of AGA2118 Q4W via SC.
Study: NCT05225857
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1 - SAD study: SAD participants in various cohorts will receive a single dose of placebo via either SC or IV.~Part 2 - MAD study: MAD participants in various cohorts will receive multiple doses of placebo via SC.
Study: NCT06417008
Drug: Aumolertinib
Normalized name: aumolertinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: 110 mg orally once daily.
Study: NCT06249633
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled nitric oxide
Study: NCT06553287
Drug: LNK01004 ointment 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNK01004 ointment 0.3% for topical application
Study: NCT06553287
Drug: LNK01004 ointment 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNK01004 ointment 1.0% for topical application
Study: NCT06553287
Drug: LNK01004 ointment 1.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNK01004 ointment 1.5% for topical application
Study: NCT05691660
Drug: TAS3731 Dose1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration,1 day,QD
Study: NCT05691660
Drug: TAS3731 Dose2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration,7 days,QD
Study: NCT05691660
Drug: TAS3731 Dose3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration,7 days,BID
Study: NCT05691660
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration, 1 day,QD
Study: NCT05691660
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration, 7 days,QD
Study: NCT05691660
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration, 7 days,BID
Study: NCT05676294
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral matched placebo one hour prior to ambulatory surgery
Study: NCT06555471
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 Bid po d1-14，q3w，Reduce or discontinue depending on the condition of the subject.
Study: NCT05043987
Drug: CPO102
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-claudin 18.2 Antibody-MMAE Drug Conjugate
Study: NCT06174116
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will take placebo for 12 weeks, in addition to their regular medications.
Study: NCT04731922
Drug: TAK-510 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-510 placebo-matching solution.
Study: NCT05027867
Drug: KRT-232
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by mouth
Study: NCT05793112
Drug: INF108F probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension
Study: NCT05793112
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension
Study: NCT04173390
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive use of Placebo oral tablet starting three days before surgery up to the third postoperative day
Study: NCT06086457
Drug: TP or PF regimen depended on investigator's choice.
Approvals — FDA: no, EMA: no, PMDA: no
Description: A maximum of six cycles was recommended for chemotherapy. Chemotherapy Regimen 1(TP regimen A): Nab-paclitaxel(Albumin-bound paclitaxel) 110-130mg/ m2，d1，d8; Cisplatin 60-75mg/ m2，d1；Q3W； Chemotherapy Regimen 2 (TP regimen B): Paclitaxel 150-175 mg/m2, d1; Cisplatin 60-75mg/ m2，d1；Q3W； PD-1 inhibitor 200mg, d1, Q3W Chemotherapy Regimen 3 (PF regimen): Capecitabine 800mg/m2, bid, d1-14; Cisplatin 25-30mg/m2, d1,d2, Q3W.
Study: NCT01108913
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05798819
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT06514001
Drug: AMDX-2011P
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMDX-2011P single bolus injection intravenous for diagnostic review
Study: NCT03570814
Drug: Administration of Azithromycin on Day 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Azithromycin 20mg/kg (max 1gm) on study day 1. Doses of Azithromycin will be determined using a standard dosing pole.
Study: NCT03570814
Drug: Administration of Azithromycin on Day 15
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive Azithromycin 20mg/kg (max 1gm) on study day 15. Doses of Azithromycin will be determined using a standard dosing pole.
Study: NCT04940676
Drug: Huzhangxiefei Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huzhangxiefei Decoction, 50ml, Oral Administered or Nasal Feeding 5 minutes after breakfast and dinner for 7 days
Study: NCT04940676
Drug: 10% Huzhangxiefei Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% Huzhangxiefei Decoction, 50ml, Oral Administered or Nasal Feeding 5 minutes after breakfast and dinner for 7 days
Study: NCT05069935
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lympho-conditioning agent
Study: NCT04950530
Drug: BIKTARVY 50Mg-200Mg-25Mg Tablet
Normalized name: Biktarvy 50mg-200mg-25mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: A three-drug fixed dose combination tablet containing 50mg of bictegravir, 200mg of emtricitabine, and 25mg of tenofovir alafenamide taken once daily, orally
Study: NCT05330208
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05170763
Drug: PA9159 nasal spray solution, 10 μg one day treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of PA9159 (5 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, one spray each in the left and right nostril.
Study: NCT05170763
Drug: PA9159 nasal spray solution, 20 μg one day treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of PA9159 (5 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
Study: NCT05170763
Drug: PA9159 nasal spray solution, 40 μg one day treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of PA9159 (10 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
Study: NCT05170763
Drug: PA9159 nasal spray solution, 80 μg one day treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of PA9159 (10 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, four sprays each in the left and right nostril.
Study: NCT05170763
Drug: PA9159 nasal spray solution, 20 μg 7-day treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated doses of PA9159 (5 μg/nasal spray) or Placebo is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
Study: NCT05170763
Drug: PA9159 nasal spray solution, 40 μg 7-day treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated doses of PA9159 (10 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
Study: NCT05170763
Drug: Placebo, the same intranasal spray solution without PA9159 active ingredient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is delivered intranasally through a metered-dose mechanical spray pump with the same volume as the corresponding PA9159 dose group
Study: NCT06029049
Drug: RSI succinylcholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be induced as per routine care using lidocaine 1 mg/kg IV, an opioid such a fentanyl (1-2 mcg/kg) IV, propofol 1-2 mg/kg IV, and succinylcholine 1mg/kg IV, and the intubation will be performed with a C-MAC
Study: NCT05081089
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing 20/80 mg artemether and 120/480 mg lumefantrine will be administered according to weight as per manufacturer guidelines.
Study: NCT05305625
Drug: standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: received standardized treatment
Study: NCT04930900
Drug: ARS-1 with URTI
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARS-1
Study: NCT04930900
Drug: ARS-1 without URTI
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARS-1 without URTI